Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

RISS Versus Lower Thoracic ESP Block for Analgesia After Laparoscopic Abdominal Surgery: A Randomized Trial

13. maj 2026 opdateret af: Emad Lotfy Mohammed Ahmed, Misr University for Science and Technology

Analgesic Efficacy of Ultrasound-Guided Rhomboid Intercostal and Subserratus (RISS) Block Versus Lower Thoracic Erector Spinae Plane Block (ESPB) After Abdominal Laparoscopic Surgery

The goal of this clinical trial is to investigate the analgesic efficacy of ultrasound-guided Romboid Intercostal and Subserratus (RISS) block versus lower thoracic Erector Spinae Plane (ESP) block after laparoscopic abdominal surgery. The main questions it aims to answer are:

Does ultrasound-guided Romboid Intercostal and Subserratus (RISS) block is effective as the lower thoracic Erector Spinae Plane (ESP) block for intra and postoperative analgesia after laparoscopic abdominal surgery for the first 24 hours? What complications do participants have when doing these interventions?

Researchers will compare the analgesic efficacy of ultrasound-guided Romboid Intercostal and Subserratus (RISS) block with the lower thoracic Erector Spinae Plane (ESP) block after laparoscopic abdominal surgery.

Participants will:

Start general anesthesia and be given either block according to the randomization chart.

The blood pressure and heart rate will be measured at intervals to determine if the participants need extra intraoperative analgesics.

Numerical Rating Scale (NRS) will be used postoperatively to test pain severity.

Rescue morphine analgesia will be measured and compared in both groups.

Any complications will be reported.

Patient and surgeon satisfaction will be measured.

Studieoversigt

Detaljeret beskrivelse

The aim of this study is to investigate the analgesic efficacy of ultrasound-guided Romboid Intercostal and Subserratus (RISS) block versus lower thoracic Erector Spinae Plane (ESP) block after laparoscopic abdominal surgery.

Hypothesis

This study hypothesize that both RISS and ESP blocks relieve somatic pain equally, but ESP block relieves visceral pain better than RISS block, thereby reducing opioid consumption and improving patient satisfaction.

Methodology using:

I. Study design

Double-blinded randomized clinical trial study.

II. Study setting and location The study will be conducted at the operative theater of Souad Kafafi University Hospital (SKUH), Misr University for Science and Technology (MUST).

III. Study population:

Patients aged from 18 to 60 years old scheduled for laparoscopic abdominal surgery will be randomized in a 1:1 ratio after induction of general anesthesia, either:

Group A: Receiving ultrasound-guided RISS block. A solution composed of 20 ml mixed xylocaine 1% + 0.25% bupivacaine + 4 mg dexamethasone on each side.

Group B: Receiving ultrasound-guided lower thoracic ESP block (T8-T9) A solution composed of 20 ml mixed xylocaine 1% + 0.25 % bupivacaine + 4 mg dexamethasone on each side.

The infiltrative local anesthesia will be administered via a 22-gauge, 80-mm Echogenic block needle.

Postoperative analgesia:

The participants in both groups will receive analgesia in accordance with the following protocol:

  • Pain will be assessed using a Numerical Rating Scale (NRS) 0-10.

    1. Mild pain (NRS 1-3) will be treated with 1 g paracetamol IV every six hours (maximum 4 g/day).
    2. Moderate pain (NRS 4-6) will receive the same paracetamol regimen plus ketorolac 30 mg IV every eight hours (maximum 120 mg/day).
    3. Severe pain (NRS 7-10) will receive the above plus 0.1 mg/kg IV morphine when indicated.

      Study outcomes:

      Primary Outcome Measure:

  • Efficacy of postoperative analgesia for first 24 hours.

Secondary Outcome Measures:

  • Total morphine equivalent consumption (mg) in 24 h.
  • Surgeon satisfaction (ability to perform active movements, 1-5 scale).
  • Patient satisfaction (1-5 scale).
  • Onset time of analgesia (min).
  • Duration of postoperative analgesia (time to first rescue).
  • Pain intensity via NRS at 2, 6, 12, 18, and 24 h.
  • Intraoperative vital signs (HR, NIBP).
  • Possible complications (pneumothorax, LAST, and vascular puncture) intra- and post-operatively.

Sample size calculation The sample size calculation was performed using G. power 3.1.9.2 (Universität Kiel, Germany). The sample size was calculated according to the total morphine dose in 24hr (4.21 in RISS vs. 4.65 in ESP) according to previous studies (9, 10). Based on the following considerations: 0.05 α error and 80% power of the study. Four cases were added to overcome dropout. Therefore, 70 patients will be allocated.

Statistical Analysis Statistical analysis will be done by SPSS v26 (IBM Inc., Chicago, IL, USA). Shapiro-Wilks test and histograms will be used to evaluate the normality of the distribution of data. Quantitative parametric variables will be presented as mean and standard deviation (SD) and compared between the two groups utilizing unpaired Student's t- test. Quantitative non-parametric data will be presented as median and interquartile range (IQR) and will be analyzed by Mann Whitney-test. Qualitative variables will be presented as frequency and percentage (%) and will be analyzed utilizing the Chi-square test or Fisher's exact test when appropriate. A two tailed P value < 0.05 will be considered statistically significant.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

70

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Giza Governorate
      • Giza, Giza Governorate, Egypten, 15525
        • Souad Kafafi University Hospital (SKUH), Faculty of Medicine, MUST

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Patients scheduled for laparoscopic abdominal surgery (e.g., cholecystectomy, colectomy, sleeve gastrectomy, hernia repair, appendectomy).
  • Age from 18 - 60 years old.
  • Both sexes.
  • American Society of Anesthesiology (ASA) classification I, II. (i.e., ASA I: a normal healthy patient; ASA II: patients with mild controlled systemic disease.

Exclusion Criteria:

  • Patients who refuse the research consent.
  • Allergy to local anesthetic drugs.
  • Cardiac arrhythmia.
  • Bleeding tendency (including pre-existing blood disease and patients on full anticoagulant therapy).
  • Morbid obese patients (BMI>35 kg/m2)
  • Vascular compromise of lower extremity (e.g., Burger disease, Raynaud's disease).
  • Connective tissue disease (e.g., Scleroderma).
  • Suspected malignancy or intra-abdominal infection.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Group A (n=35): Ultrasound-guided RISS block.
The patient will be positioned in the lateral decubitus with the ipsilateral arm abducted to move the scapula laterally and open the intercostal and subscapular spaces. A high-frequency linear probe (10-14 MHz) will be applied 1-2 cm medial to the medial scapular border in an oblique-sagittal plane at the T5-T6 level. Using an in-plane approach, a 22 G, 80 mm block needle will be advanced from superomedial to inferolateral (cephalocaudal) until the tip lies between RM and ICM. After negative aspiration and hydrodissection with 1-2 ml saline, 10 ml of the prepared solution (1% lidocaine + 0.25% bupivacaine + 4 mg dexamethasone) will be injected in 5 ml aliquots, with real-time observation of spread deep to RM. The probe will then be slid caudally and laterally to the T8-T9 level to visualize the fascial plane at the mid-axillary line between the serratus anterior (SA) muscle and the external intercostal muscle to inject the other 10 ml of local anesthetic.
The patient will be positioned in the lateral decubitus with the ipsilateral arm abducted to move the scapula laterally and open the intercostal and subscapular spaces. A high-frequency linear probe (10-14 MHz) will be applied 1-2 cm medial to the medial scapular border in an oblique-sagittal plane at the T5-T6 level. Using an in-plane approach, a 22 G, 80 mm block needle will be advanced from superomedial to inferolateral (cephalocaudal) until the tip lies between RM and ICM. After negative aspiration and hydrodissection with 1-2 ml saline, 10 ml of the prepared solution (1% lidocaine + 0.25% bupivacaine + 4 mg dexamethasone) will be injected in 5 ml aliquots, with real-time observation of spread deep to RM. The probe will then be slid caudally and laterally to the T8-T9 level to visualize the fascial plane at the mid-axillary line between the serratus anterior (SA) muscle and the external intercostal muscle to inject the other 10 ml of local anesthetic.
Aktiv komparator: Group B (n=35): Receiving ultrasound-guided lower thoracic ESP block
The patient will be positioned laterally. A linear probe will be placed 3 cm lateral to the posterior midline at the T8-T9 level to identify the transverse process (TP) and erector spinae muscle (ESM). A 22 G, 80 mm Echogenic block needle will be advanced in-plane from cranial to caudal until the tip rests deep to ESM but superficial to the TP. After negative aspiration, 20 ml of the prepared solution (1% lidocaine + 0.25% bupivacaine + 4 mg dexamethasone) will be injected in 5 ml aliquots, with real-time ultrasound confirmation of longitudinal spread cranially and caudally along the fascial plane. The block will be performed bilaterally following the same stepsA solution composed of 20 ml mixed xylocaine 1% + 0.25 % bupivacaine + 4 mg dexamethasone on each side.
The patient will be positioned laterally. A linear probe will be placed 3 cm lateral to the posterior midline at the T8-T9 level to identify the transverse process (TP) and erector spinae muscle (ESM). A 22 G, 80 mm Echogenic block needle will be advanced in-plane from cranial to caudal until the tip rests deep to ESM but superficial to the TP. After negative aspiration, 20 ml of the prepared solution (1% lidocaine + 0.25% bupivacaine + 4 mg dexamethasone) will be injected in 5 ml aliquots, with real-time ultrasound confirmation of longitudinal spread cranially and caudally along the fascial plane. The block will be performed bilaterally following the same stepsA solution composed of 20 ml mixed xylocaine 1% + 0.25 % bupivacaine + 4 mg dexamethasone on each side.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Postoperative analgesia
Tidsramme: from 0 to 24 hours postoperative

Pain will be assessed using a Numerical Rating Scale (NRS) (0-10 scale).

Will be measured by NRS at 0, 6, 12, 18, and 24 hours postoperative

  1. Mild pain (NRS 1-3) will be treated with 1 g paracetamol IV every six hours (maximum 4 g/day).
  2. Moderate pain (NRS 4-6) will receive the same paracetamol regimen plus ketorolac 30 mg IV every eight hours (maximum 120 mg/day).
  3. Severe pain (NRS 7-10) will receive the above plus 0.1 mg/kg IV morphine when indicated.
from 0 to 24 hours postoperative

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Total morphine consumption (mg) in 24 h.
Tidsramme: from 0 to 24 hours postoperative
Doses of morphine given intravenous postoperatively according to severity of pain (NRS > 6) during the first 24 hours postoperatively
from 0 to 24 hours postoperative
Intra-operative vital signs (HR)
Tidsramme: Before induction of anesthesia till the end of surgery
Measuring the patient's heart rate (HR) before induction of anesthesia and every 15 minutes during surgery.
Before induction of anesthesia till the end of surgery
• Intra-operative vital signs: Mean Blood Pressure (MBP)
Tidsramme: Before induction of anesthesia till the end of surgery
Measuring the patient's Mean Blood Pressure (MBP) before induction of anesthesia and every 15 minutes during surgery.
Before induction of anesthesia till the end of surgery
Possible complications
Tidsramme: Intra- and post-operatively for 24 hours.
pneumothorax, LAST, vascular puncture
Intra- and post-operatively for 24 hours.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studiestol: Manar M ElKholy, Profesor, Prof. of Anesth, Kasr Alainy hospital, Faculty of Medicine, Cairo University
  • Studieleder: Mohamed Abdelaziz Taha, Assist. Prof., Assist. Prof. of Anesth, Souad Kafafi University hospital, Faculty of Medicine, MUST
  • Studieleder: Ahmed SK Elkhodary, Lecturer, Lecturer of surgery at Souad Kafafi University hospital, Faculty of Medicine, MUST

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

20. maj 2026

Primær færdiggørelse (Anslået)

31. december 2026

Studieafslutning (Anslået)

31. december 2026

Datoer for studieregistrering

Først indsendt

28. april 2026

Først indsendt, der opfyldte QC-kriterier

13. maj 2026

Først opslået (Faktiske)

18. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2025/0124

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Demographic Information: Age, sex, race, and other relevant demographic details.

Baseline Characteristics: Health status, medical history, and any pre-existing conditions prior to the trial.

Treatment Assignment: Information on the intervention or treatment each participant received.

Outcome Measures: Data on primary and secondary outcomes as defined in the trial protocol.

Adverse Events: Reports of any side effects or adverse events experienced by participants during the trial.

Follow-up Data: Information collected during follow-up periods, including long-term outcomes

IPD-delingstidsramme

may 2026 to December 2026

IPD-delingsadgangskriterier

Researchers:

Who: Academic researchers, industry scientists, and regulatory agencies. What: Full IPD, including demographic data, treatment assignments, and outcome measures.

How: Through data sharing platforms or repositories after submitting a research proposal and obtaining necessary approvals.

Regulatory Authorities:

Who: Agencies like the FDA or EMA. What: Full IPD and supporting documentation for oversight and review. How: Direct access during the review process of clinical trial applications.

Data Sharing Initiatives:

Who: Collaborating institutions and consortia. What: Aggregated or anonymized IPD for meta-analyses or systematic reviews. How: Via established partnerships and shared databases.

Public and Patient Advocacy Groups:

Who: Organizations seeking to promote transparency. What: Summary data and aggregated results, but not individual-level data. How: Through publicly available reports or dashboards.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Smerter efter operationen

Abonner